Itonis Inc (ITNS)

[lordofinvest]

Just a reminder, ITNS is not a PR company. 2012 year research coverage By Goldman Research before all the recent development to completion of the manufacturing. We are at that stage now where ITNS can start to market aggressively. VERY BULLISH! After some setbacks which they have overcome with this level @.014 with support, Sky is the limit. Good weekend.

"Goldman Small Cap Research believes ITNS is an Trading Opportunity! They concluded that ITNS was undervalued by a staggering discount - They have Placed a $.27 Price Target on ITNS!!! Here is their reasoning:

The bottom line with ITNS is that this is a bet on Dr. Hensley, which in our view, is a solid bet. With limited competition and major advantages over other existing offerings, the Itonis Pharmaceuticals anti-nausea product should be huge for the Company and other Itonis products will likely ride the coattails of success next year as well.
Given the history of Hensley’s product development and marketing success, we believe that the ITNS pharmaceutical division alone could achieve $100M in sales within 3 years. Our $0.27 price target reflects 1x this preliminary revenue forecast and does not include the potential value of Paramount, which could be significant to shareholders once licensing and commercialization occur."